Adam Kaplin is the Chief Scientific Officer of MyMD Pharmaceuticals. Kaplin’s research focuses on the investigation of the biological basis of immune mediated depression and cognitive impairment by using MS as the model. Previously, Kaplin has served as Principal Neuro-Psychiatric Consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence, Director of the Johns Hopkins Ketamine Clinic and the Departments of Psychiatry & Neurology at Johns Hopkins University School of Medicine. He was also an Adjunct Faculty at the George Mason University Department of Global and Community Health.

Kaplin received his B.S. in Biology from Yale University, and his M.D. and Ph.D. from the Johns Hopkins University School of Medicine.